The last few years have represented an exciting and promising time in the field of migraine, thanks to the introduction of several new medications in clinical practice, and with other therapeutic targets, such as glutamate, amylin, adrenomedullin, orexins and pituitary adenylate cyclase activating polypeptide, currently all in the therapeutic pipeline [114, 115]. Here, ADCYAP1 is linked to migraine disorder.